71 A new study has found that higher levels of inflammation in the body before surgery are associated with worse survival rates in patients with mucinous appendix cancer. The findings, published in the European Journal of Surgical Oncology, suggest that a common blood test measuring C-reactive protein could help doctors identify patients who may need closer monitoring or additional treatments. Researchers analysed data from 273 patients who underwent cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, a complex procedure used to treat appendix cancer that has spread within the abdomen. They found that patients with lower-grade tumours and elevated preoperative C-reactive protein levels had significantly worse progression-free and overall survival compared to those with lower inflammation levels. In contrast, for patients with more aggressive high-grade tumours, preoperative inflammation did not appear to have the same impact on survival outcomes. The study highlights the growing recognition of inflammation’s role in cancer progression. While inflammation is known to drive tumour development in many cancers, its influence in appendix cancer has been less understood. The researchers suggest that high levels of C-reactive protein may indicate a more aggressive disease course in certain subtypes of the cancer. The findings could help refine prognosis assessments and guide treatment decisions by integrating inflammation markers into patient evaluations. Mucinous appendix cancer is a rare condition, but when it spreads, it can be challenging to treat. The study provides further evidence that systemic inflammation may contribute to poor outcomes, especially in patients with lower-grade tumours. By identifying patients with elevated inflammation, doctors could consider more aggressive follow-up strategies to monitor for recurrence and improve survival chances. Future research may explore whether anti-inflammatory treatments could play a role in managing appendix cancer in combination with standard therapies. The results offer a potential step forward in personalised cancer care. By incorporating C-reactive protein testing into routine preoperative assessments, oncologists may be able to tailor treatment plans more effectively. While further research is needed, the study adds to the growing body of evidence suggesting that inflammation is not just a symptom of cancer but could be a crucial factor influencing its progression and treatment response.